Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours

Proteomics

Volumn 13, Issue 10-11, 2013, Pages 1595-1607

  Garnier, Delphine ^a   Jabado, Nada ^a   Rak, Janusz ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Biomedicine; Brain; Cancer; Exosomes; Extracellular vesicles; Oncogenes

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; BETA CATENIN; CD63 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; CELL PROTEIN; CHAPERONE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 70; HISTONE; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NUCLEIC ACID; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLSERINE; PHOSPHOPROTEIN; PHOSPHOSPECIFIC ANTIBODY; PROTEIN BCL XL; PROTEIN KINASE B; RAB27A PROTEIN; RAS PROTEIN; RHO FACTOR; SPHINGOMYELIN PHOSPHODIESTERASE; TRANSCRIPTION FACTOR; VASCULOTROPIN;

BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CELL MEMBRANE; CELL VACUOLE; ENZYME ACTIVITY; EXOSOME; GENE AMPLIFICATION; GLIOMA; HOST CELL; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MICROFLUIDICS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CONTENT; PROTEOMICS; REVIEW; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; EXOSOMES; GLIOMA; HUMANS; ONCOGENE PROTEINS; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84878654194     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200360     Document Type: Review

References (139)

1. Steeg, P. S., Camphausen, K. A., Smith, Q. R., Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 2011, 11, 352-363.
2. Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S. et al., Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113, 1953-1968.
3. Wrensch, M., Minn, Y., Chew, T., Bondy, M. et al., Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002, 4, 278-299.
4. Zhu, Y., Parada, L. F., The molecular and genetic basis of neurological tumours. Nat. Rev. Cancer 2002, 2, 616-626.
5. Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F. et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157-173.
6. Li, J., Sulman, E., Aldape, K., Molecular biology of brain tumors. Handb. Clin. Neurol. 2012, 104, 23-34.
7. Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V. et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98-110.
8. Wen, P. Y., Kesari, S., Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492-507.
9. Northcott, P. A., Korshunov, A., Pfister, S. M., Taylor, M. D., The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 2012, 8, 340-351.
10. Biernat, W., Huang, H., Yokoo, H., Kleihues, P. et al., Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004, 14, 131-136.
11. Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M. et al., Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20, 810-817.
12. Wu, X., Northcott, P. A., Dubuc, A., Dupuy, A. J. et al., Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012, 482, 529-533.
13. Dirks, P. B., Brain tumor stem cells: bringing order to the chaos of brain cancer. J. Clin. Oncol. 2008, 26, 2916-2924.
14. Faury, D., Nantel, A., Dunn, S. E., Guiot, M. C. et al., Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 2007, 25, 1196-1208.
15. Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T. et al., Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482, 226-231.
16. Ohgaki, H., Kleihues, P., Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009, 100, 2235-2241.
17. Jones, C., Perryman, L., Hargrave, D., Paediatric and adult malignant glioma: close relatives or distant cousins? Nat. Rev. Clin. Oncol. 2012, 9, 400-413.
18. Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A. et al., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353, 2012-2024.
19. Vivanco, I., Robins, H. I., Rohle, D., Campos, C. et al., Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012, 2, 458-471.
20. Inda, M. M., Bonavia, R., Mukasa, A., Narita, Y. et al., Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24, 1731-1745.
21. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P. et al., Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284, 1994-1998.
22. Brat, D. J., Van Meir, E. G., Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Invest. 2004, 84, 397-405.
23. Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A. et al., Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20, 1487-1495.
24. Rak, J., Guha, A., Extracellular vesicles-vehicles that spread cancer genes. Bioessays 2012, 34, 489-497.
25. Thery, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9, 581-593.
26. van der Vos, K. E, Balaj, L., Skog, J., Breakefield, X. O., Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cell. Mol. Neurobiol. 2011, 31, 949-959.
27. Wolf, P., The nature and significance of platelet products in human plasma. Br. J. Haematol. 1967, 13, 269-288.
28. Anderson, H. C., Vesicles associated with calcification in the matrix of epiphyseal cartilage. J. Cell Biol. 1969, 41, 59-72.
29. Taylor, D. D., Doellgast, G. J., Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal. Biochem. 1979, 98, 53-59.
30. Dvorak, H. F., Quay, S. C., Orenstein, N. S., Dvorak, A. M. et al., Tumor shedding and coagulation. Science 1981, 212, 923-924.
31. Harding, C., Heuser, J., Stahl, P., Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 1983, 97, 329-339.
32. Pan, B. T., Johnstone, R. M., Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33, 967-978.
33. Dolo, V., D'Ascenzo, S., Giusti, I., Millimaggi, D. et al., Shedding of membrane vesicles by tumor and endothelial cells. Ital. J. Anat. Embryol. 2005, 110, 127-133.
34. Sadallah, S., Eken, C., Schifferli, J. A., Ectosomes as modulators of inflammation and immunity. Clin. Exp. Immunol. 2011, 163, 26-32.
35. Giesen, P. L., Rauch, U., Bohrmann, B., Kling, D. et al., Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. USA 1999, 96, 2311-2315.
36. Simpson, R. J., Lim, J. W., Moritz, R. L., Mathivanan, S., Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics 2009, 6, 267-283.
37. Di Vizio, D., Kim, J., Hager, M. H., Morello, M. et al., Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009, 69, 5601-5609.
38. Piccin, A., Murphy, W. G., Smith, O. P., Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007, 21, 157-171.
39. Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A., Souza-Schorey, C., Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 2010, 123, 1603-1611.
40. Gyorgy, B., Szabo, T. G., Pasztoi, M., Pal, Z. et al., Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011, 68, 2667-2688.
41. Bianco, F., Perrotta, C., Novellino, L., Francolini, M. et al., Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J. 2009, 28, 1043-1054.
42. Mathivanan, S., Fahner, C. J., Reid, G. E., Simpson, R. J., ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012, 40(Database issue), D1241-D1244.
43. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M. et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659.
44. Skog, J., Wurdinger, T., van, Rijn S., Meijer, D. H. et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10, 1470-1476.
45. Bolukbasi, M. F., Mizrak, A., Ozdener, G. B., Madlener, S. et al., miR-1289 and "zipcode"-like sequence enrich mRNA in microvesicles. Journal of Extracellular Vesicles 2012, 1, 2.
46. Shen, B., Wu, N., Yang, J. M., Gould, S. J., Protein targeting to exosomes/microvesicles by plasma membrane anchors. J. Biol. Chem. 2011, 286, 14383-14395.
47. Del Conde, I., Shrimpton, C. N., Thiagarajan, P., Lopez, J. A., Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005, 106, 1604-1611.
48. Al-Nedawi, K., Meehan, B., Micaleff, J., Guha, A. et al., Phosphoproteome of tumour derived microvesicles as a source of biomarkers to monitor the effects of targeted agents in glioblastoma. (Abstract), Society of Neurooncology, Annual Meeting, Montreal 2010.
49. Turola, E., Furlan, R., Bianco, F., Matteoli, M. et al., Microglial microvesicle secretion and intercellular signaling. Front. Physiol. 2012, 3, ahead of print.
50. Taylor, D. D., Gercel-Taylor, C., MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110, 13-21.
51. Zwicker, J. I., Trenor, C. C. III, Furie, B. C., Furie, B., Tissue factor-bearing microparticles and thrombus formation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 728-733.
52. Tesselaar, M. E., Romijn, F. P., van der Linden, I., Prins, F. A. et al., Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost. 2007, 5, 520-527.
53. Ghosh, A. K., Secreto, C. R., Knox, T. R., Ding, W. et al., Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115, 1755-1764.
54. Gross, P. L., Furie, B. C., Merrill-Skoloff, G., Chou, J. et al., Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J. Leukoc. Biol. 2005, 78, 1318-1326.
55. Wang, J. G., Geddings, J. E., Aleman, M. M., Cardenas, J. C. et al., Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012, 23, 5543-5552.
56. Al-Nedawi, K., Meehan, B., Rak, J., Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009, 8, 2014-2018.
57. Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V. et al., Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008, 10, 619-624.
58. Graner, M. W., Alzate, O., Dechkovskaia, A. M., Keene, J. D. et al., Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009, 23, 1541-1557.
59. Koga, K., Matsumoto, K., Akiyoshi, T., Kubo, M. et al., Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005, 25, 3703-3707.
60. Yu, J. L., May, L., Lhotak, V., Shahrzad, S. et al., Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005, 105, 1734-1741.
61. Yu, X., Harris, S. L., Levine, A. J., The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66, 4795-4801.
62. Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L. et al., Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319, 1244-1247.
63. Muralidharan-Chari, V., Clancy, J., Plou, C., Romao, M. et al., ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr. Biol. 2009, 19, 1875-1885.
64. Antonyak, M. A., Li, B., Boroughs, L. K., Johnson, J. L. et al., Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc. Natl. Acad. Sci. USA 2011, 108, 4852-4857.
65. Li, B., Antonyak, M. A., Zhang, J., Cerione, R. A., RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene 2012, 31, 4740-4749.
66. Orlowski, R. Z., Eswara, J. R., Lafond-Walker, A., Grever, M. R. et al., Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58, 4342-4348.
67. Lespagnol, A., Duflaut, D., Beekman, C., Blanc, L. et al., Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 2008, 15, 1723-1733.
68. Al-Nedawi, K., Meehan, B., Kerbel, R. S., Allison, A. C. et al., Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. USA 2009, 106, 3794-3799.
69. Holmgren, L., Szeles, A., Rajnavolgyi, E., Folkman, J. et al., Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 1999, 93, 3956-3963.
70. Chen, C., Skog, J., Hsu, C. H., Lessard, R. T. et al., Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 2010, 10, 505-511.
71. Garcia-Olmo, D. C., Dominguez, C., Garcia-Arranz, M., Anker, P. et al., Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010, 70, 560-567.
72. Hood, J. L., San, R. S., Wickline, S. A., Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011, 71, 3792-3801.
73. Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I. et al., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med 2012, 18, 833-891.
74. Jung, T., Castellana, D., Klingbeil, P., Cuesta, Hernandez, I. et al., CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11, 1093-1105.
75. Gesierich, S., Berezovskiy, I., Ryschich, E., Zoller, M., Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 2006, 66, 7083-7094.
76. Deregibus, M. C., Cantaluppi, V., Calogero, R., Lo, Iacono M. et al., Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007, 110, 2440-2448.
77. Thomas, G. M., Panicot-Dubois, L., Lacroix, R., gnat-George, F. et al., Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J. Exp. Med. 2009, 206, 1913-1927.
78. Jaiswal, R., Gong, J., Sambasivam, S., Combes, V. et al., Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J. 2012, 26, 420-429.
79. Wolfers, J., Lozier, A., Raposo, G., Regnault, A. et al., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7, 297-303.
80. Kim, J. W., Wieckowski, E., Taylor, D. D., Reichert, T. E. et al., Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005, 11, 1010-1020.
81. Grange, C., Tapparo, M., Collino, F., Vitillo, L. et al., Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71, 5346-5356.
82. Gril, B., Evans, L., Palmieri, D., Steeg, P. S., Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur. J. Cancer 2010, 46, 1204-1210.
83. Schettino, C., Bareschino, M. A., Rossi, A., Maione, P. et al., Targeting angiogenesis for treatment of NSCLC brain metastases. Curr. Cancer Drug Targets 2012, 12, 289-299.
84. Kikuchi, T., Daigo, Y., Ishikawa, N., Katagiri, T. et al., Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int. J. Oncol. 2006, 28, 799-805.
85. Saunus, J. M., Momeny, M., Simpson, P. T., Lakhani, S. R. et al., Molecular aspects of breast cancer metastasis to the brain. Genet. Res. Int. 2011, 2011, 1-9.
86. Bos, P. D., Zhang, X. H., Nadal, C., Shu, W. et al., Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459, 1005-1009.
87. Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G. et al., The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012, 486, 346-352.
88. Paugh, B. S., Broniscer, A., Qu, C., Miller, C. P. et al., Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin. Oncol. 2011, 29, 3999-4006.
89. Pfister, S., Witt, O., Pediatric gliomas. Recent Results Cancer Res. 2009, 171, 67-81.
90. Rheinbay, E., Louis, D. N., Bernstein, B. E., Suva, M. L., A tell-tail sign of chromatin: histone mutations drive pediatric glioblastoma. Cancer Cell 2012, 21, 329-331.
91. Pfister, S., Janzarik, W. G., Remke, M., Ernst, A. et al., BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 2008, 118, 1739-1749.
92. Jacob, K., Albrecht, S., Sollier, C., Faury, D. et al., Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br. J. Cancer 2009, 101, 722-733.
93. Kool, M., Korshunov, A., Remke, M., Jones, D. T. et al., Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123, 473-484.
94. Deighton, R. F., McGregor, R., Kemp, J., McCulloch, J. et al., Glioma pathophysiology: insights emerging from proteomics. Brain Pathol. 2010, 20, 691-703.
95. Li, F., Glinskii, O. V., Zhou, J., Wilson, L. S. et al., Identification and analysis of signaling networks potentially involved in breast carcinoma metastasis to the brain. PLoS One 2011, 6, e21977.
96. Zhang, H., Wang, Y., Chen, Y., Sun, S. et al., Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 2007, 57, 37-45.
97. Rajagopal, M. U., Hathout, Y., MacDonald, T. J., Kieran, M. W. et al., Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: a pediatric brain tumor consortium study. Proteomics 2011, 11, 935-943.
98. Zanini, C., Mandili, G., Bertin, D., Cerutti, F. et al., Analysis of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF. Childs Nerv. Syst. 2011, 27, 2077-2085.
99. Somasundaram, K., Nijaguna, M. B., Kumar, D. M., Serum proteomics of glioma: methods and applications. Expert Rev. Mol. Diagn. 2009, 9, 695-707.
100. He, J., Liu, Y., Zhu, T. S., Xie, X. et al., Glycoproteomic analysis of glioblastoma stem cell differentiation. J. Proteome Res. 2011, 10, 330-338.
101. Shi, Q., Qin, L., Wei, W., Geng, F. et al., Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc. Natl. Acad. Sci. USA 2012, 109, 419-424.
102. Hill, J. J., Moreno, M. J., Lam, J. C., Haqqani, A. S. et al., Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label-free quantification. Proteomics 2009, 9, 535-549.
103. Com, E., Clavreul, A., Lagarrigue, M., Michalak, S. et al., Quantitative proteomic isotope-coded protein label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J. Proteomics 2012, 75, 3898-3913.
104. Guo, T., Wang, W., Rudnick, P. A., Song, T. et al., Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J. Histochem. Cytochem. 2007, 55, 763-772.
105. Khalil, A. A., Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007, 98, 201-213.
106. Khwaja, F. W., Svoboda, P., Reed, M., Pohl, J. et al., Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 2006, 25, 7650-7661.
107. Wang, Y., Rudnick, P. A., Evans, E. L., Li, J. et al., Proteome analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS. Anal. Chem. 2005, 77, 6549-6556.
108. Iwadate, Y., Sakaida, T., Hiwasa, T., Nagai, Y. et al., Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res. 2004, 64, 2496-2501.
109. Koncarevic, S., Urig, S., Steiner, K., Rahlfs, S. et al., Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes. Free Radic. Biol. Med. 2009, 46, 1096-1108.
110. Melchior, K., Tholey, A., Heisel, S., Keller, A. et al., Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J. Proteome Res. 2009, 8, 4604-4614.
111. Wu, G., Feng, X., Stein, L., A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010, 11, R53.
112. Collet, B., Guitton, N., Saikali, S., Avril, T. et al., Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci. 2011, 9, 2-14.
113. Formolo, C. A., Williams, R., Gordish-Dressman, H., MacDonald, T. J. et al., Secretome signature of invasive glioblastoma multiforme. J. Proteome Res. 2011, 10, 3149-3159.
114. Polisetty, R. V., Gupta, M. K., Nair, S. C., Ramamoorthy, K. et al., Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins. J. Proteomics 2011, 74, 1918-1925.
115. Mustafa, D. A., Dekker, L. J., Stingl, C., Kremer, A. et al., A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma. Mol. Cell. Proteomics 2012, 11, M111.
116. Gollapalli, K., Ray, S., Srivastava, R., Renu, D. et al., Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 2012, 12, 2378-2390.
117. Nilsson, C. L., Dillon, R., Devakumar, A., Shi, S. D. et al., Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J. Proteome Res. 2010, 9, 430-443.
118. Fang, X., Wang, C., Balgley, B. M., Zhao, K. et al., Targeted tissue proteomic analysis of human astrocytomas. J. Proteome Res. 2012, 11, 3937-3946.
119. de Saldanha da Gama Fischer J., Costa Carvalho P., da Fonseca, C. O., Liao, L. et al., Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol. J. Proteome Res. 2011, 10, 153-160.
120. Shim, J. H., Kim, Y. S., Bahk, Y. Y., Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells. Proteomics 2006, 6, 81-93.
121. Lai, C. P., Breakefield, X. O., Role of exosomes/ microvesicles in the nervous system and use in emerging therapies. Front. Physiol. 2012, 3, ahead of print.
122. Taylor, D. D., Zacharias, W., Gercel-Taylor, C., Exosome isolation for proteomic analyses and RNA profiling. Methods Mol. Biol. 2011, 728, 235-246.
123. Henderson, M. C., Azorsa, D. O., The genomic and proteomic content of cancer cell-derived exosomes. Front. Oncol. 2012, 3, ahead of print.
124. Raimondo, F., Morosi, L., Chinello, C., Magni, F. et al., Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics 2011, 11, 709-720.
125. Balaj, L., Lessard, R., Dai, L., Cho, Y. J. et al., Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2011, 2, 1-9.
126. Misale, S., Yaeger, R., Hobor, S., Scala, E. et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486, 532-536.
127. Diehl, F., Schmidt, K., Choti, M. A., Romans, K. et al., Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14, 985-990.
128. Thaler, J., Ay, C., Mackman, N., Bertina, R. M. et al., Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J. Thromb. Haemost. 2012, 10, 1363-1370.
129. Sheldon, H., Heikamp, E., Turley, H., Dragovic, R. et al., New mechanism for Notch signaling to endothelium at a distance by delta-like 4 incorporation into exosomes. Blood 2010, 116, 2385-2394.
130. Lo Cicero, A., Schiera, G., Proia, P., Saladino, P. et al., Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes. Int. J. Oncol. 2011, 39, 1353-1357.
131. Shao, H., Chung, J., Balaj, L., Charest, A. et al., Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Med. 2012, 18, 1835-1841.
132. Fang, Y., Wu, N., Gan, X., Yan, W. et al., Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol. 2007, 5, e158.
133. Epple, L. M., Griffiths, S. G., Dechkovskaia, A. M., Dusto, N. L. et al., Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS One 2012, 7, e42064.
134. Rak, J, Al-Nedawi, K., Meehan, B., Guha, A., Tumor cell-derived microvesicles, 2010, CIP-05001770-379US-1.
135. Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D. et al., Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 2009, 20, 363-379.
136. Kang, D., Oh, S., Ahn, S. M., Lee, B. H. et al., Proteomic analysis of exosomes from human neural stem cells by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry. J. Proteome Res. 2008, 7, 3475-3480.
137. Dragovic, R. A., Gardiner, C., Brooks, A. S., Tannetta, D. S. et al., Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine 2011, 7, 780-788.
138. Lacroix, R., Judicone, C., Poncelet, P., Robert, S. et al., Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J. Thromb. Haemost. 2012, 10, 437-446.
139. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C. et al., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341-345.